Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With Oral Nilotinib.
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Nilotinib (Primary) ; Imatinib
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- 30 Jan 2020 Results (data cut off: December 31, 2016) assessing long-term efficacy and safety data from the trial after a median follow-up of 78.3 months published in the Cancer
- 04 Dec 2018 Results after 5.7 years of follow up (n=22, data cut off: 30 Jun 2018) presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
- 26 Jul 2018 Status changed from active, no longer recruiting to completed.